Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1993 1
1994 1
1995 1
1996 1
1997 1
1998 3
1999 2
2000 1
2001 1
2002 1
2003 1
2004 3
2007 1
2008 1
2009 1
2010 1
2011 1
2013 2
2014 4
2015 2
2016 4
2017 2
2018 1
2019 1
2020 3
2021 6
2022 4
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Unresectable Cervical Adenocarcinoma"
Page 1
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma.
Song X, Kelley RK, Khan AA, Standifer N, Zhou D, Lim K, Krishna R, Liu L, Wang K, McCoon P, Negro A, He P, Gibbs M, Kurland JF, Abou-Alfa GK. Song X, et al. Clin Cancer Res. 2023 Feb 16;29(4):754-763. doi: 10.1158/1078-0432.CCR-22-1983. Clin Cancer Res. 2023. PMID: 36477555 Free PMC article. Clinical Trial.
This study evaluated the pharmacokinetics, exposure-response, and exposure-pharmacodynamics relationships of tremelimumab in patients with unresectable hepatocellular carcinoma (uHCC). PATIENTS AND METHODS: A previous tremelimumab population pharmacokinetic model was valid …
This study evaluated the pharmacokinetics, exposure-response, and exposure-pharmacodynamics relationships of tremelimumab in patients with …
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen DT, Berglund A, Michael L, Aoki M, Wang MH, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS. Kim S, et al. Lancet. 2022 Sep 24;400(10357):1008-1019. doi: 10.1016/S0140-6736(22)01659-2. Epub 2022 Sep 12. Lancet. 2022. PMID: 36108657 Free PMC article. Clinical Trial.
Eligible patients were aged at least 18 years with histologically proven advanced stage (unresectable, recurrent, or stage IV) Merkel cell carcinoma, a minimum of two tumour lesions measureable by CT, MRI or clinical exam, and tumour tissue available for exploratory biomar …
Eligible patients were aged at least 18 years with histologically proven advanced stage (unresectable, recurrent, or stage IV) Merkel …
Pembrolizumab for the treatment of esophageal cancer.
Yamamoto S, Kato K. Yamamoto S, et al. Expert Opin Biol Ther. 2020 Oct;20(10):1143-1150. doi: 10.1080/14712598.2020.1792881. Epub 2020 Jul 14. Expert Opin Biol Ther. 2020. PMID: 32620063 Review.
INTRODUCTION: Esophageal cancer (EC) is the seventh most common cancer and the sixth leading cause of cancer death. However, the prognosis of unresectable advanced or recurrent EC patients remains poor and there are few effective therapeutic agents for EC. ...
INTRODUCTION: Esophageal cancer (EC) is the seventh most common cancer and the sixth leading cause of cancer death. However, the prognosis o …
PD-L1 expression in sebaceous carcinomas.
Saliba M, Shaheen M, Hajj RE, Abbas F, Bashir S, Sheikh UN, Mahfouz R, Loya A, Khalifeh I. Saliba M, et al. Cancer Immunol Immunother. 2021 Jul;70(7):1907-1915. doi: 10.1007/s00262-020-02821-3. Epub 2021 Jan 4. Cancer Immunol Immunother. 2021. PMID: 33398391 Free PMC article.
BACKGROUND: Traditional systemic treatments for unresectable, recurrent, and/or advanced sebaceous carcinoma (SC) are ineffective. ...PD-L1 percentage was assessed amongst tumor (PD-L1 + Tu) and immune infiltrating cells (PD-L1 + Inf). Each case was attributed a combined p …
BACKGROUND: Traditional systemic treatments for unresectable, recurrent, and/or advanced sebaceous carcinoma (SC) are ineffective. .. …
Diagnosis of esophagogastric tumors.
Moretó M. Moretó M. Endoscopy. 2003 Jan;35(1):36-42. doi: 10.1055/s-2003-36398. Endoscopy. 2003. PMID: 12510224 Review.
Esophageal squamous-cell carcinoma appears to be commonly associated with head and neck cancer, but the cost-effectiveness of surveillance is a matter of controversy. With regard to Barrett's esophagus and adenocarcinoma, p53 staining in areas of low-grade dysplasia …
Esophageal squamous-cell carcinoma appears to be commonly associated with head and neck cancer, but the cost-effectiveness of surveil …
The SINTART 2 Study. A phase II non-randomised controlled trial of induction chemotherapy, photon-, proton- and carbon-ion-based radiotherapy integration in patients with locally advanced unresectable sinonasal tumours.
Bossi P, Orlandi E, Resteghini C, Vischioni B, Nicolai P, Castelnuovo P, Gambazza S, Locati LD, Turri-Zanoni M, Ferrari M, Facchinetti N, Iacovelli NA, Calareso G, Quattrone P, Cavallo A, Tuzi A, Licitra L. Bossi P, et al. Eur J Cancer. 2023 Jul;187:134-143. doi: 10.1016/j.ejca.2023.03.034. Epub 2023 Apr 7. Eur J Cancer. 2023. PMID: 37163806 Clinical Trial.
PURPOSE: Unresectable, locally advanced sinonasal epithelial tumours are rare diseases with poor prognosis. ...This study assessed activity and safety of an innovative integration of multimodality treatment-induction chemotherapy (ICT), surgery and radiotherapy (RT)-modula …
PURPOSE: Unresectable, locally advanced sinonasal epithelial tumours are rare diseases with poor prognosis. ...This study assessed ac …
The prognostic implications from molecular testing of thyroid cancer.
Ozgursoy OB, Eisele DW, Tufano RP. Ozgursoy OB, et al. Otolaryngol Clin North Am. 2014 Aug;47(4):595-607. doi: 10.1016/j.otc.2014.04.010. Otolaryngol Clin North Am. 2014. PMID: 25041960 Review.
To date, there are no prospective, well-defined data supporting the use of molecular markers alone to decide the extent of treatment of patients with thyroid cancer or to predict the individual prognosis of these patients. Molecular markers are promising in the development …
To date, there are no prospective, well-defined data supporting the use of molecular markers alone to decide the extent of treatment of pati …
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.
Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y, Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu RH; RATIONALE-305 Investigators. Qiu MZ, et al. BMJ. 2024 May 28;385:e078876. doi: 10.1136/bmj-2023-078876. BMJ. 2024. PMID: 38806195 Clinical Trial.
PARTICIPANTS: 1657 patients aged 18 years with human epidermal growth factor receptor 2 negative locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma, regardless of programmed death-ligand 1 (PD-L1) expression status, who …
PARTICIPANTS: 1657 patients aged 18 years with human epidermal growth factor receptor 2 negative locally advanced unresectable or met …
miR-552 promotes the proliferation and metastasis of intrahepatic cholangiocarcinoma by targeting FOXO1.
Cheng Z, Cheng N, Tang X, Yang F, Ma W, Yu Q, Tang H, Xiao Q, Lei Z. Cheng Z, et al. Exp Cell Res. 2023 Oct 1;431(1):113741. doi: 10.1016/j.yexcr.2023.113741. Epub 2023 Aug 5. Exp Cell Res. 2023. PMID: 37549804
Few effective systemic targeted therapies are available for patients with unresectable ICC, but there exists an urgent need to explore mechanisms underlying the initiation and progression of ICC. ...Recently, the biological function of a novel miRNA, miR-552, has been wide …
Few effective systemic targeted therapies are available for patients with unresectable ICC, but there exists an urgent need to explor …
Outcomes of nonsurgical management of locally advanced carcinomas of the sinonasal cavity.
Chopra S, Kamdar DP, Cohen DS, Heilbrun LK, Smith D, Kim H, Lin HS, Jacobs JR, Yoo G. Chopra S, et al. Laryngoscope. 2017 Apr;127(4):855-861. doi: 10.1002/lary.26228. Epub 2016 Nov 15. Laryngoscope. 2017. PMID: 27859278 Free PMC article.
RESULTS: Female (57%) and Caucasian (74%) preponderance were observed. Eighty-seven percent were unresectable; the maxillary and nasoethmoid sites were equally prevalent. ...Platinum agents were given in 95% of chemotherapy patients. Complete response was observe …
RESULTS: Female (57%) and Caucasian (74%) preponderance were observed. Eighty-seven percent were unresectable; the maxillary a …
52 results